Erschienen in:
01.06.2005 | Correspondence
The Authors’ Reply
verfasst von:
Lynda V Wilton, Monika Kollarova, Emma Heeley, Saad Shakir
Erschienen in:
Drug Safety
|
Ausgabe 6/2005
Einloggen, um Zugang zu erhalten
Excerpt
We thank Dr Elliott for his comments on our paper and are interested to learn of the recent publications in which antifungal activity of the selective serotonin reuptake inhibitor (SSRI) antidepressants has been demonstrated
in vitro and in three cases of recurrent vulvovaginal candidiasis. Young et al.[
1] concluded from the results of their study that the concentrations of SSRIs that are required for antifungal activity are associated with significant toxic effects on human cells. They also concluded that SSRIs are unlikely to be useful in the development of other products with a more specific mode of action. …